IRVINE, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that ReproSource, Inc., a nationally-recognized laboratory dedicated to fertility specialists and the patients they serve, is now offering CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. ReproSource, based just outside of Boston, Massachusetts, is an international clinical reference laboratory providing specialized diagnostic services for unexplained infertility, recurrent pregnancy loss and premature ovarian failure.
"We have found CombiMatrix's quality service to their physicians and patients to be consistent with our approach," said Charles Jenkins, Vice President of ReproSource. "We look forward to offering our nationwide network of fertility specialists and fertility centers the opportunity to use CombiMatrix's test offerings to help their patients."
Mark McDonough, Chief Executive Officer of CombiMatrix, said, "ReproSource has an outstanding reputation in the fertility testing industry, and we view this partnership as a noteworthy validation of the quality of our tests and the ancillary counselling services we provide in this important new market for us. As we expand our focus to the care of fertility patients, we are pleased to offer our high touch, high quality service to ReproSource and their client base while concurrently benefitting from ReproSource's expertise and customer reach with reproductive endocrinologists."
Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians, reproductive endocrinologists, fertility doctors and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.
"Historically, unclear results from genetic testing of products of conception has been frequent, which makes diagnosing the cause of miscarriage difficult and frustrating for both clinicians and patients," said Benjamin Leader, M.D., Ph.D., the Director of Clinical Research at ReproSource. "The type of genetic testing provided by CombiMatrix significantly increases the frequency with which we can provide reliable answers to our physicians and their patients."
ReproSource is a clinical reference laboratory and research organization that exists to provide clinicians and patients alike with the best solutions for fertility testing and education. ReproSource publishes some of the largest studies in the world related to fertility testing, and works both nationally and internationally with fertility experts to provide the best in patient care and clinical research. ReproSource continually works to refine research, validate results and update the fertility testing used for initial patient diagnostic evaluations. ReproSource empowers clinicians and patients to make the most informed decisions in the treatment of recurring pregnancy loss and unexplained infertility.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in miscarriage analysis, prenatal testing and pediatric genetics, offering DNA‑based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization ("FISH") and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding the access to our services for ReproSource, Inc.'s physicians. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: use of our services by ReproSource patients; market acceptance of CMA as a superior method of molecular diagnostic testing; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
CONTACT: Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: Robert Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 firstname.lastname@example.org Media Contact: David Schull or Lena Evans Russo Partners LLC (212) 845-4271 (212) 845-4262 email@example.com firstname.lastname@example.org